Jingfang Liu

Dr. Jingfang Liu

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2020 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
JLJingfang Liu
Jingfang Liu
QLQingxiu Li
Qingxiu Li
YYYaxian Yang
Yaxian Yang
LMLihua Ma
Lihua Ma
Aims/Introduction: Iron metabolism can directly or indirectly affect the occurrence and development of type 2 diabetes. This meta‐analysis and systematic review aimed to analyze the association between serum iron metabolism indicators and type 2 diabetes.Materials and Methods: The databases PubMed and Embase were searched for studies on the correlations between serum iron metabolism indicators (iron, ferritin, transferrin, hepcidin and soluble transferrin receptor) and type 2 diabetes since January 2006. Relevant data were extracted from the included studies, and meta‐analysis was carried out.Results: A total of 12 case–control and cohort studies were analyzed. Of the 12 studies, 11 described the correlation between serum ferritin levels and type 2 diabetes. The median and high serum ferritin concentrations were significantly associated with the risks of type 2 diabetes (odds ratio [OR] 1.20, 95% confidence interval [CI] 1.08–1.33 and OR 1.43, 95% CI 1.29–1.59, respectively). However, the low concentration was not correlated with the risk of type 2 diabetes (OR 0.99, 95% CI 0.89–1.11). No significant association was observed between serum soluble transferrin receptor and type 2 diabetes, whereas the soluble transferrin receptor‐to‐ferritin ratio was significantly inversely related to the risk of type 2 diabetes in the median and high ratio subgroups (OR 0.71, 95% CI 0.51, 0.99 and OR 0.65, 95% CI 0.45–0.95).Conclusions: The elevated serum ferritin was one of the risk factors for type 2 diabetes, and soluble transferrin receptor‐to‐ferritin ratio was inversely related to the risk of type 2 diabetes. A systematic review showed that serum transferrin and hepcidin might be directly or indirectly related to the development of diabetes.

28 June 2022 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
BPBinjing Pan
Binjing Pan
JCJing Cai
Jing Cai
PZPingping Zhao
Pingping Zhao
JLJingfang Liu
Jingfang Liu
SFSongbo Fu
Songbo Fu
QLQiong Li
Qiong Li

20 April 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
YZYangting Zhao
Yangting Zhao
BPBinjing Pan
Binjing Pan
XLXiaoyu Lv
Xiaoyu Lv
CCChongyang Chen
Chongyang Chen
KLKai Li
Kai Li
JLJingfang Liu
Jingfang Liu
Diabetic cardiomyopathy (DCM) is a serious complication of type 1 and type 2 diabetes, which leads to the aggravation of myocardial fibrosis, disorders involving systolic and diastolic functions, and increased mortality of patients with diabetes through mechanisms such as glycolipid toxicity, inflammatory response, and oxidative stress. Ferroptosis is a form of iron-dependent regulatory cell death that is attributed to the accumulation of lipid peroxides and an imbalance in redox regulation. Increased production of lipid reactive oxygen species (ROS) during ferroptosis promotes oxidative stress and damages myocardial cells, leading to myocardial systolic and diastolic dysfunction. Overproduction of ROS is an important bridge between ferroptosis and DCM, and ferroptosis inhibitors may provide new targets for the treatment of patients with DCM.

1 February 2024 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
XLXiaoyu Lv
Xiaoyu Lv
HWHui Wang
Hui Wang
CCChongyang Chen
Chongyang Chen
YZYangting Zhao
Yangting Zhao
KLKai Li
Kai Li
JLJingfang Liu
Jingfang Liu
To explore the effects of Tirzepatide (TZP), a new hypoglycemic drug, on weight, blood lipids and blood pressure in overweight/obese patients with type 2 diabetes mellitus (T2DM). Relevant studies investigating the influence of TZP therapy on weight, lipid profiles and blood pressure in overweight/obese T2DM patients were selected from the PubMed, Embase, Web of Science and Cochrane databases from establishment until November 2022. A systematic review and meta-analysis were conducted to evaluate the effect of TZP on weight, blood lipids and blood pressure in overweight/obese patients with T2DM. Eight randomized controlled trials (RCTs), comprising 7491 patients with T2DM, were included in the meta-analysis. Results showed that compared with the glucagon-like peptide-1 receptor agonist (GLP-1RA), insulin, and placebo groups, body weight, triglycerides (TG), very low-density lipoprotein cholesterol (VLDL-C), total cholesterol (TC), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), and glycosylated hemoglobin (HbA1c) levels were significantly decreased in the TZP-treated groups, while high-density lipoprotein cholesterol (HDL-C) levels increased. With the gradual increase of TZP doses, the proportions of T2DM patients with weight loss >5% gradually increased. The 10 mg and 15 mg TZP doses had a stronger effect on the levels of TG, VLDL-C, and HDL-C. Moreover, the reduction in SBP levels in the 15 mg TZP-treated group was more pronounced than those in the 10 mg and 5 mg TZP-treated groups [MD=−2.07, 95% CI (−2.52, −1.63) and MD=−3.14, 95% CI (−4.42, −1.87)]. Compared with GLP-1RA, insulin, and placebo groups, the proportions of patients with HbA1c<7% in 10mg and 15mg TZP-treated groups were significantly higher than in the 5mg TZP-treated group [OR=1.53, 95% CI (1.25, 1.8)], OR=1.7, 95% CI (1.15, 2.50)].There was no significant difference regarding the risk of adverse reactions.

22 December 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PZPingping Zhao
Pingping Zhao
XLXiaoyu Lv
Xiaoyu Lv
ZZZhicong Zhou
Zhicong Zhou
XYXiaolan Yang
Xiaolan Yang
YHYing Huang
Ying Huang
JLJingfang Liu
Jingfang Liu
Objective: To explore the correlations between diabetic nephropathy (DN) and serum levels of glutathione peroxidase 4 (GPX4), acyl-CoA synthetase long-chain family member 4 (ACSL4), iron, transferrin (Tf), and ferritin in patients with type 2 diabetes mellitus (T2DM).Methods: According to the urinary albumin excretion rate(UAER) or estimated glomerular filtration rate (eGFR) levels, a total of 123 patients with T2DM were separately divided into normoalbuminuria (NO), microalbuminuria (MI), macroalbuminuria (MA) groups, and G1 (eGFR ≥ 90 mL/min), G2 (eGFR ≤ 60 mL/min to < 90 mL/min), and G3 groups (eGFR< 60 mL/min), with 33 healthy participants as the control (HC). The differences in serum GPX4, ACSL4, iron, Tf, and ferritin levels between groups were compared, and the relationships between these levels were analysed. The independent correlations between UAER or DN severity and serum GPX4, ACSL4, iron, Tf, and ferritin levels were analysed by multiple linear and multinomial logistic regression, respectively.Results: To the patients with T2DM, with the increase in UAER levels, GPX4, iron, and Tf levels gradually decreased, whereas ACSL4 levels increased, meanwhile with the decrease in eGFR levels, GPX4 and Tf levels gradually decreased, whereas ACSL4 levels increased. UAER were independently and positively correlated with ACSL4 [β = 17.53, 95% confidence interval (CI; 11.94, 23.13)] and negatively correlated with GPX4 [β = −1.633, 95% CI (−2.77, -0.496)] and Tf [β = −52.94, 95% CI (-95.78, −10.11)].The NO and MI groups were considered as reference groups, respectively. The severity of DN was negatively correlated with serum GPX4 [odds ratio (OR) = 0.925 and 0.902, p =0.015 and 0.001], and Tf (OR = 0.109 and 0.119, p =0.043 and 0.034), and positively correlated with ACSL4 (OR = 1.952 and 1.865, both p &lt;0.001) in the MA group.Conclusion: DN severity was negatively correlated with serum GPX4 and Tf levels and positively correlated with serum ACSL4 levels in patients with T2DM.

17 February 2024 in Endocrine
Verified
Journal Article
Closed access
PDF file
BPBinjing Pan
Binjing Pan
YZYangting Zhao
Yangting Zhao
CCChongyang Chen
Chongyang Chen
JCJing Cai
Jing Cai
KLKai Li
Kai Li
JLJingfang Liu
Jingfang Liu